Article: article from journal or magazin.
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
Publication types: Journal Article ; Review Publication Status: ppublish
Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with colorectal carcinoma. However, these therapies are effective only in a subset of patients. Activating mutations in the KRAS gene are found in 30-40% of colorectal tumors and are associated with poor response to anti-EGFR therapies. Thus, KRAS mutation status can predict which patient may or may not benefit from anti-EGFR therapy. Although many diagnostic tools have been developed for KRAS mutation analysis, validated methods and standardized testing procedures are lacking. This poses a challenge for the optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Here we review the molecular basis of EGFR-targeted therapies and the resistance to treatment conferred by KRAS mutations. We also present guideline recommendations and a proposal for a European quality assurance program to help ensure accuracy and proficiency in KRAS mutation testing across the European Union.
Antibodies/therapeutic use, Colorectal Neoplasms/drug therapy, Colorectal Neoplasms/genetics, Europe, Genetic Testing, Humans, Point Mutation/genetics, Predictive Value of Tests, Proto-Oncogene Proteins/genetics, Quality Assurance, Health Care, Receptor, Epidermal Growth Factor/antagonists & inhibitors, Receptor, Epidermal Growth Factor/immunology, ras Proteins/genetics
Web of science
Last modification date